Powerful new weight-loss drug helps patients cut knee pain in half
In two phase 3 trials involving more than 1,000 people with knee osteoarthritis, the experimental drug retatrutide was linked to substantial weight loss and less knee pain. The results matter because painful knees can make exercise difficult, while excess weight can worsen the strain and symptoms. At the highest dose, participants lost an average of about 25% of their body weight. Combining results from both trials, researchers found that roughly two-thirds of retatrutide recipients reported at least a 50% reduction in knee pain. Among participants given a placebo, 38% reported that degree of relief. The trials also found reductions in blood pressure, blood lipid levels, and inflammation. Findings were published in the New England Journal of Medicine on Nov. 8. The studies do not establish whether retatrutide prevents further joint damage, and the medication remains experimental. Lifestyle changes remain an important starting point for managing weight and osteoarthritis.
What did the trials find about retatrutide’s effects on body weight and knee pain?
In two phase 3 trials involving more than 1,000 people with knee osteoarthritis, the experimental drug retatrutide was linked to substantial weight loss and less knee pain. The results matter because painful knees can make exercise difficult, while excess weight can worsen the strain and symptoms.
At the highest dose, participants lost an average of about 25% of their body weight. Combining results from both trials, researchers found that roughly two-thirds of retatrutide recipients reported at least a 50% reduction in knee pain. Among participants given a placebo, 38% reported that degree of relief.
The trials also found reductions in blood pressure, blood lipid levels, and inflammation. Findings were published in the New England Journal of Medicine on Nov. 8. The studies do not establish whether retatrutide prevents further joint damage, and the medication remains experimental. Lifestyle changes remain an important starting point for managing weight and osteoarthritis.
How much weight did people on the highest dose lose, and how many had their knee pain cut by at least half?
The most striking combined result was that roughly two-thirds of people taking retatrutide reported their knee pain had fallen by at least half. The finding comes from two phase 3 trials of an experimental injectable drug in people with knee osteoarthritis. It offers a possible new approach for people whose pain and excess weight can make daily movement difficult.
People receiving the highest dose lost an average of about 25% of their body weight. The pain result combines participants in both trials; by comparison, 38% of those given a placebo reported a reduction of at least 50%. Researchers said reduced weight means less load on the knees, which can help ease pain and improve function.
These results are promising, but they do not show that the drug prevents joint damage. Retatrutide is still experimental, and the article does not report its effect on knee replacement. Lifestyle changes remain a starting point, while medication side effects and cost are relevant considerations.
What is retatrutide, and how does its three-hormone-receptor action differ from drugs such as semaglutide?
Retatrutide is an experimental weight-loss medication developed by Eli Lilly and given as a once-weekly injection. It matters because the phase 3 trials found large weight reductions in people who also had painful knee osteoarthritis. Researchers are studying whether this approach can help people who struggle to lose substantial weight through lifestyle changes alone.
The article says retatrutide activates receptors associated with three different naturally occurring hormones. That differs from existing medicines such as semaglutide, which acts on one hormone receptor; tirzepatide acts on two. In the trials, participants taking retatrutide lost about 20% to 25% of their body weight, depending on the dose. The article does not name the three hormones.
Retatrutide remains experimental, so the trial findings do not make it an established treatment. Researchers reported less knee pain as well as weight loss, but whether the medication can prevent further joint damage is unknown. The article also notes potential GLP-1 drug side effects, including gastrointestinal problems and muscle loss.
Why can carrying less body weight reduce the pain and strain placed on knees?
Carrying less body weight can reduce the load placed on the knees during movement. This matters for people with knee osteoarthritis, whose pain can make walking, climbing stairs, or rising from a chair difficult. The article identifies reduced knee loading as a major reason substantial weight loss may ease pain and help people function better.
Corresponding author Thomas Schnitzer explained that losing significant weight means “you're loading your knees less” and therefore may experience less pain. Retatrutide participants lost about 20% to 25% of their body weight, depending on dose. Across the two trials, roughly two-thirds reported at least a 50% reduction in knee pain, compared with 38% given placebo.
The results support a link between weight loss and symptom relief, but they do not prove that less weight stops osteoarthritis from damaging the joint. The article says the drug’s ability to prevent further joint damage remains unknown. Weight loss through diet and exercise is also an established way to improve symptoms, though substantial loss can be difficult.
Do these trials show that retatrutide slows joint damage or helps people avoid knee replacement?
The trials found substantial weight loss and less reported knee pain, but they do not establish that retatrutide slows osteoarthritis damage. That distinction matters: feeling better is not the same as showing that a joint’s structure is being preserved. The article specifically says the drug’s ability to prevent further joint damage remains unknown.
Across the two studies, roughly two-thirds of retatrutide recipients reported at least a 50% reduction in knee pain, compared with 38% of placebo recipients. Participants at the highest dose lost about 25% of their body weight on average. Researchers suggested that reduced loading on the knees helps explain the pain relief, but the article does not report evidence about cartilage changes or other structural outcomes.
The article also does not say whether participants avoided or delayed knee replacement. The findings were published in the New England Journal of Medicine, and trial results were presented at a medical meeting. Retatrutide remains experimental; longer-term evidence would be needed to answer questions about joint damage or replacement.
What other ways can people with knee osteoarthritis manage pain or lose weight, and what trade-offs do they have?
People with knee osteoarthritis have several options in the article: physical therapy, medicines applied to the skin, oral anti-inflammatory drugs such as ibuprofen and Voltaren, opioids, and corticosteroid injections. Weight loss through diet and exercise can also improve symptoms. These approaches matter because they may ease pain or address excess weight without relying on an experimental drug.
Earlier studies cited in the article found that losing 5% to 10% of body weight through diet and exercise can improve knee osteoarthritis pain. But losing more than 10% this way is often challenging, especially when painful knees make exercise difficult. Steroid injections can help, but their relief generally lasts only a short time.
Schnitzer says lifestyle changes should remain the starting point. They avoid the expense of newer weight-loss medicines and side effects associated with GLP-1 drugs, including gastrointestinal problems and muscle loss. Retatrutide may offer another route to larger weight loss, but it remains experimental. Strengthening muscles matters too, since muscles around the joint help support and stabilize it.
What happens to cartilage and other parts of the knee joint in osteoarthritis?
The source article focuses on weight loss and knee pain; it does not describe what happens inside an osteoarthritic knee. In general medical knowledge, osteoarthritis involves the breakdown of cartilage, the smooth tissue that cushions the ends of bones in a joint. As that protection becomes damaged, movement can become painful and stiff.
The disease can also involve tissues beyond cartilage. The bone beneath the cartilage may change, and the joint lining can become irritated or inflamed. These changes can contribute to pain, swelling, and difficulty moving. The article does not report that retatrutide repaired cartilage or changed any of these joint structures.
The trials measured weight loss and reported knee pain, among other health measures. About two-thirds of participants taking retatrutide reported at least a 50% reduction in pain, but whether the drug prevents further joint damage remains unknown. So symptom relief in these results should not be taken as proof that the underlying joint changes have stopped.
This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.
Read more in the JupiteX app
Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.
Or read more news on the web